Submitting a paper to Leukemia & Lymphoma
Before preparing your submission, please visit the journal’s website for a complete style guide:
http://www.informahealthcare.com/lal All submissions should be made online at Leukemia & Lymphoma’s Manuscript Central site
http://mc.manuscriptcentral.com/glal New users should first create an account. Once a user is logged onto the site submissions should be made via the Author Centre.
Copyright. It is a condition of publication that authors assign copyright or license the publication rights in their articles, including abstracts, to Informa UK, Ltd. This enables us to ensure full copyright protection and to disseminate the article, and of course the Journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa, provided that acknowledgement is given to the Journal as the original source of publication, and that Informa is notified so that our records show that its use is properly authorised. Authors retain a number of other rights under the Informa rights policies documents.
These policies are referred to at
http://www.informaworld.com/smpp/authors_journals_copyright for full details. Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
Please note that Informa UK, Ltd. are signatories of, and respect the spirit of, the STM agreement regarding the free sharing and dissemination of scholarly information.
Colour Charges:
The journal has a limited number of free colour pages within its annual page allowance. Authors should consult the editorial office with respect to colour reproduction at submission stage. Any figure submitted as a colour original may appear in colour within the journal’s online edition. Colour reproduction in excess of the journals budget will only be considered on condition that authors contribute to the associated costs.
Offprints and Reprints: Offprints and reprints of articles published in this journal can be purchased once the article has been published online. Corresponding authors will receive free online access to their article through the journal website (
http://www.informahealthcare.com/lal). Reprints of articles published in this journal can be purchased through Rightslink® when proofs are received. Copies of the Journal can be purchased at the authors’ preferential rate of $25.00 per copy.
Clinical Trials Registry:
In accordance with the guidelines published by the International Committee of Medical Journal Editors (ICMJE) and the changes to the policy published in an ICMJE Editorial in June 2007, Leukemia & Lymphoma requires that all clinical trials activated after Jan 1 2006 be registered in a public repository at their inception and prior to patient enrolment.
The registry must be accessible to the public at no charge, be open to all prospective registrants and managed by a not-for-profit organization. For a list of registries that meet all of these requirements, please see the WHO International Clinical Trials Registry Platform (ICTRP) (
http://www.who.int/ictrp/en/). For more information, see ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals (
http://www.icmje.org).
The registration of all clinical trials facilitates the dissemination of information among clinicians, researchers and patients, and enhances public confidence in the research enterprise.
Editorial Office: Leukemia & Lymphoma c/o Didi Peng Managing Editor, Telephone House Informa Healthcare 69–77 Paul Street, London, EC2A 4LQ UK
E-mail:
Didi.peng@
informa.com
Aims and Scope Leukemia & Lymphoma is an international journal that publishes full-length papers and reviews on clinical and therapeutic practice, epidemiological studies and outcomes analysis, laboratory diagnosis, pathology, cytology, ultrastructure, cytogenetics and cellular and molecular immunology of hematologic malignancies; the journal aims at a strong clinical-pathologic correlation. Letters and correspondence to the editors are also accepted on all topics, which are novel and provide new and interesting data for clinicians and postgraduate teaching. In addition, an update is provided on the basic issues and advances in molecular genetics as applied to this field. The journal will provide an important reference source for physicians and scientists who deal essentially with the clinical and laboratory diagnosis, clinical care and therapy of patients with these disorders.
(SUB 09/09)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122